AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26165396 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 1555
Study 26165396 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention (diet and physical activity).
Number of subjects: 1555
Study 24995901 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory electrical stimulation (AES)
Number of subjects: 44
Study 24995901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PES)
Number of subjects: 44
Study 20041881 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina Plan (AP)
Number of subjects: 218
Study 20041881 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 218
Study 19745641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg single dose of triazolam
Number of subjects: 49
Study 19745641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg divided between 2 equal doses for 60 minutes
Number of subjects: 49
Study 19745641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg divided among 3 doses for 90 minutes
Number of subjects: 49
Study 19745641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16524479 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare rights advice
Number of subjects: 126
Study 15269853 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal preflaring using size 25# and 20# ProFile.06 taper NiTi rotary instrument
Number of subjects: 48
Study 15269853 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group 1)
Number of subjects: 48
Study 11730260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 184
Study 11730260 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (combined data from both studies)
Number of subjects: 184
Study 11730260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 184
Study 9150326 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ASA (90 mg x mL(‐1))
Number of subjects: 12
Study 9150326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine, 30 mg x mL(‐1))
Number of subjects: 12
Study 7716955 — intervention group
Group type: EXPERIMENTAL
Intervention: Olicard 40 (isosorbide mononitrate)
Number of subjects: 52
Study 7716955 — intervention group
Group type: COMPARATOR
Intervention: Cardonit 40 (isosorbide dinitrate)
Number of subjects: 52
Study 2465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention
Number of subjects: 0
Study 2465581 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30048027 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (64 mmol daily)
Number of subjects: 209
Study 30048027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 26043561 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome differentiation based acupuncture (Group A)
Number of subjects: 70
Study 26043561 — intervention group
Group type: COMPARATOR
Intervention: Ordinary acupuncture (Group B)
Number of subjects: 70
Study 22258186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagger's hybrid technique
Number of subjects: 70
Study 22258186 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 70
Study 22258186 — intervention group
Group type: COMPARATOR
Intervention: Thermafil system
Number of subjects: 70
Study 21799810 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV3B
Number of subjects: 50
Study 21799810 — intervention group
Group type: COMPARATOR
Intervention: Inflexal®V
Number of subjects: 50
Study 19031076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine treatment (25 mg/kg body weight, orally on three consecutive days)
Number of subjects: 40
Study 17073869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to a sunny subtropical climate (Gran Canary) for 4 weeks
Number of subjects: 56
Study 17073869 — intervention group
Group type: COMPARATOR
Intervention: Home in Norway (control group)
Number of subjects: 56
Study 15327407 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1046
Study 15327407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study 11194533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) emulsion
Number of subjects: 40
Study 11194533 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 g-DG emulsion
Number of subjects: 40
Study 11194533 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol (TG) emulsion
Number of subjects: 40
Study 9258482 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 50 IU/kg
Number of subjects: 366
Study 9258482 — intervention group
Group type: COMPARATOR
Intervention: Heparin 100 IU/kg
Number of subjects: 366
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II alleles (specifically DR3 and DR4 haplotypes)
Number of subjects: 42
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II alleles (specifically DRB1*1402)
Number of subjects: 42
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: DR-DQ DR4 haplotypes bearing DQB1*0302
Number of subjects: 42
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1 allele
Number of subjects: 42
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Asp-57 in the HLA-DQ beta chain
Number of subjects: 42
Study 7981758 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1 and DQB1
Number of subjects: 42
Study 3300583 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator and dipyridamole
Number of subjects: 44
Study 3300583 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator and no dipyridamole
Number of subjects: 44
Study 3300583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with dipyridamole
Number of subjects: 44
Study 3300583 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator without dipyridamole
Number of subjects: 44
Study 30185733 — intervention group
Group type: COMPARATOR
Intervention: Nusinersen (Spinraza®)
Number of subjects: 0
Study 24617349 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein (25 grams daily, 91 mg of aglycone weight isoflavones: 52 mg genistein, 36 mg daidzein, 3 mg glycitein)
Number of subjects: 350
Study 24617349 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein
Number of subjects: 350
Study 24617349 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma isoflavonoid levels
Number of subjects: 350
Study 24617349 — intervention group
Group type: COMPARATOR
Intervention: Milk protein-matched placebo
Number of subjects: 350
Study 23754821 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted SSRO
Number of subjects: 8
Study 23754821 — intervention group
Group type: COMPARATOR
Intervention: Conventional SSRO
Number of subjects: 8
Study 19896204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine + weak variable magnetic field (VIOFOR JPS device)
Number of subjects: 30
Study 19896204 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine + placebo (VIOFOR JPS device in placebo mode)
Number of subjects: 30
Study 18549459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-Phosphatidylcholine (PC)
Number of subjects: 125
Study 18549459 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 125
Study 21146375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement in positive affect during the first week of treatment
Number of subjects: 49
Study 21146375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early change in negative emotions
Number of subjects: 49
Study 16195989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise (athletes)
Number of subjects: 20
Study 16195989 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin iontophoresis (0.1 ml Humulin R 100 IU/ml diluted 1/10 with 0.9 % saline)
Number of subjects: 20
Study 16195989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia response
Number of subjects: 20
Study 11805506 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical netilmicin
Number of subjects: 209
Study 11805506 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 209
Study 11805506 — intervention group
Group type: COMPARATOR
Intervention: Topical netilmicin and Gentamicin
Number of subjects: 209
Study 9809091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting point needles (50-mm-long 25G Quincke and 25-mm-long 26G Atraucan)
Number of subjects: 200
Study 9809091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil point needles (37-mm-long 27G Whitacre and 35-mm-long 24G Sprotte)
Number of subjects: 200
Study 9809091 — intervention group
Group type: EXPERIMENTAL
Intervention: All needles
Number of subjects: 200
Study 9809091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil point needles
Number of subjects: 200
Study 8573661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 369
Study 8573661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 369
Study 8573661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg
Number of subjects: 369
Study 8573661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 2667209 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath-1M (10-day course postoperatively) + high-dose cyclosporine (17 mg/kg)
Number of subjects: 0
Study 2667209 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-dose cyclosporine alone)
Number of subjects: 0
Study 28687 — intervention group
Group type: EXPERIMENTAL
Intervention: H 87/07
Number of subjects: 33
Study 28687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11445789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (DEX) 0.6 mg/kg, maximum 16 mg for 2 days
Number of subjects: 533
Study 11445789 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (PRED) 2 mg/kg, maximum 60 mg for 5 days
Number of subjects: 533
Study 31171963 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality technology (5-min exposure to the operating room)
Number of subjects: 40
Study 31171963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual reality exposure)
Number of subjects: 40
Study 28945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in noncaffeine consumers
Number of subjects: 14
Study 28945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine
Number of subjects: 14
Study 28945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in noncaffeine consumers (isometric)
Number of subjects: 14
Study 28945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine (isometric)
Number of subjects: 14
Study 26228448 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 8953
Study 26228448 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8953
Study 26228448 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate chronic kidney disease
Number of subjects: 8953
Study 26228448 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chronic kidney disease
Number of subjects: 8953
Study 26228448 — intervention group
Group type: COMPARATOR
Intervention: Normal/mild chronic kidney disease
Number of subjects: 8953
Study 24583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 43
Study 24583931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 22483479 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone (QNL)
Number of subjects: 109
Study 22483479 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (RFP)
Number of subjects: 109
Study 22483479 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone-conversion (QNL-C)
Number of subjects: 109
Study 22483479 — intervention group
Group type: COMPARATOR
Intervention: Rifampin-maintenance (RFP-M)
Number of subjects: 109
Study 21355378 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (175 mg per week for 3 weeks, followed by 75 mg or 25 mg per week)
Number of subjects: 162
Study 21355378 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (higher dose)
Number of subjects: 162
Study 21355378 — intervention group
Group type: COMPARATOR
Intervention: Control group (various other treatments)
Number of subjects: 162
Study 21355378 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (both dose regimens)
Number of subjects: 162
Study 17684084 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (≥6 months)
Number of subjects: 100
Study 17684084 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ADT (<6 months)
Number of subjects: 100
Study 17684084 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no prostate cancer)
Number of subjects: 100
Study 17684084 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 100
Study 15718193 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping information about breast self-examinations
Number of subjects: 202
Study 15718193 — intervention group
Group type: COMPARATOR
Intervention: Low-affirmation condition
Number of subjects: 202
Study 15718193 — intervention group
Group type: COMPARATOR
Intervention: High-affirmation condition
Number of subjects: 202
Study 15718193 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exposure to breast cancer
Number of subjects: 202
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain unit
Number of subjects: 972
Study 14631055 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigestion or burning-type pain
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain radiating to the left arm
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain radiating to the right arm
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomiting
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous smoking
Number of subjects: 972
Study 14631055 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 972
Study 10463902 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments (specific details not provided)
Number of subjects: 0
Study 10463902 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice guidelines based on evidence from randomised controlled trials
Number of subjects: 0
Study 8680091 — intervention group
Group type: EXPERIMENTAL
Intervention: Navelbine and cisplatin (NVB-P)
Number of subjects: 612
Study 8680091 — intervention group
Group type: COMPARATOR
Intervention: Vindesine and cisplatin (VDS-P)
Number of subjects: 612
Study 8680091 — intervention group
Group type: COMPARATOR
Intervention: Navelbine alone (NVB)
Number of subjects: 612
Study 1877960 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 1877960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7033578 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 100
Study 7033578 — intervention group
Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 100
Study 7033578 — intervention group
Group type: COMPARATOR
Intervention: General US population
Number of subjects: 100
Study 31631602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-volume ventilation during CPB
Number of subjects: 60
Study 31631602 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilation (Control)
Number of subjects: 60
Study 28993940 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Number of subjects: 115
Study 28993940 — intervention group
Group type: COMPARATOR
Intervention: Prefilled applicator
Number of subjects: 115
Study 26142452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 3408
Study 26142452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study 24145210 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism induction
Number of subjects: 0
Study 24145210 — intervention group
Group type: COMPARATOR
Intervention: No optimism
Number of subjects: 0
Study 22453323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 446
Study 22453323 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (pelvic floor muscle training and continence strategies)
Number of subjects: 446
Study 22453323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 446
Study 22453323 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study 20708452 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (10 training sessions in 5 weeks)
Number of subjects: 80
Study 20708452 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (n=40)
Number of subjects: 80
Study 20708452 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (in subgroup with somatosensoric tinnitus)
Number of subjects: 80
Study 17692594 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental-fill/occlusal irradiation technique
Number of subjects: 70
Study 17692594 — intervention group
Group type: COMPARATOR
Intervention: Bulk-fill/transtooth irradiation method
Number of subjects: 70
Study 17692594 — intervention group
Group type: COMPARATOR
Intervention: Single shade translucent material
Number of subjects: 70
Study 15866684 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/d
Number of subjects: 256
Study 15866684 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/d
Number of subjects: 256
Study 15866684 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 256
Study 12145567 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 10221663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily for 8 weeks
Number of subjects: 24
Study 10221663 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg daily for 8 weeks
Number of subjects: 24
Study 10221663 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 24
Study 8567551 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright cycle exercise at 60% VO2peak in warm environments (22 and 36 degrees C)
Number of subjects: 12
Study 8567551 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright cycle exercise at 60% VO2peak
Number of subjects: 12
Study 2142866 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of epidural sufentanil (5 micrograms/h)
Number of subjects: 40
Study 2142866 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of lumbar epidural morphine (0.5 mg/h)
Number of subjects: 40
Study 673790 — intervention group
Group type: EXPERIMENTAL
Intervention: VM 26 (60 mg/m2), methyl‐C.C.N.U. (120 mg/m2) and 5 fluoro‐uracile
Number of subjects: 39
Study 673790 — intervention group
Group type: COMPARATOR
Intervention: B.C.G. (simultaneous application)
Number of subjects: 39
Study 31516010 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg per day for six weeks
Number of subjects: 68
Study 31516010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metformin)
Number of subjects: 68
Study 28689855 — intervention group
Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org (PYL)
Number of subjects: 385
Study 28689855 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 385
Study 25218708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (40 mg/m(2) every 21 days)
Number of subjects: 79
Study 25218708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (40 mg/m(2) every 21 days) with cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2) once weekly)
Number of subjects: 79
Study 25218708 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 79
Study 24413659 — intervention group
Group type: EXPERIMENTAL
Intervention: MECALF (motivational enhancement and conditioning activity for leg function) intervention delivered by WOC nurses for 6 weeks.
Number of subjects: 21
Study 24413659 — intervention group
Group type: COMPARATOR
Intervention: CALF (conditioning activities for lower leg function) provided by site staff (not WOC nurses).
Number of subjects: 21
Study 24413659 — intervention group
Group type: EXPERIMENTAL
Intervention: MECALF intervention
Number of subjects: 21
Study 22549501 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) using time points at C(1h)-C(2h)-C(4h)
Number of subjects: 71
Study 22549501 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) using time points at C(1h)-C(1.5h)-C(2h)-C(4h)
Number of subjects: 71
Study 19201709 — intervention group
Group type: EXPERIMENTAL
Intervention: lab‐PM (portable monitoring in the laboratory)
Number of subjects: 157
Study 19201709 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐PM (portable monitoring at home)
Number of subjects: 157
Study 19201709 — intervention group
Group type: COMPARATOR
Intervention: PSG (polysomnography)
Number of subjects: 157
Study 17288854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (group A)
Number of subjects: 100
Study 17288854 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy and pre-medication (group B)
Number of subjects: 100
Study 15251161 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with vitamin C, vitamin E and selenium dissolved in a beverage
Number of subjects: 48
Study 15251161 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 48